A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.
20511
Phase 1 other active
Quick answer
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment. for Prostate cancer is a Phase 1 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Prostate cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active